drugset / Trial / NCT01679080

The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta

NCT01679080

Phase 2 Terminated 9 enrolled University of Aarhus
RandomizedParallel-groupOpen-labelTreatment

Summary

Osteogenesis imperfecta (OI) is an inherited disease of the connective tissue. Symptoms are fractures, growth retardation, blue sclera, bad teeth, impaired hearing a.o. The aim of the present study is to investigate the effect of treatment of adult OI patients with bisphosphonate (zoledronic acid), parathyroid hormone (PTH) or placebo on bone mass, fracture risk and quality of life. The investigators will therefore conduct a double blind, placebo controlled trial, taking genotype and previous antiresorptive therapy into account.

Timeline

Start
2012-11
Primary completion
2020-07-01
Completion
2021-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic
Subject Zoledronic acid Other / unclassified 5 mg Intravenous